Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point?
For the past 25 years, manufacturers of orphan drugs have faced few obstacles to reimbursement from private or public insurers, despite prices that can amount to hundreds of thousands of dollars annually in treatment cost. However, payer sensitivity appears to be rising, as the launch rate of orphan drugs accelerates amid increasing pressure to contain costs.
Orphan Drugs: The Potential Impact of Generic Biologics
As the number of patients with diabetes increases, there is growing concern about the adequacy of reimbursement levels for delivering comprehensive diabetes care.
Diabetes Management Strategies: More Money Does Not Equal Better Care
Hypertension affects approximately 1 of 3 adults in the United States, and about 2 million new cases are diagnosed each year.1,2 An additional 28% of the US population is afflicted with prehypertension, and approximately 7% of Americans are not aware that they even have hypertension.3 Globally, hypertension affects more than 1 billion people and is projected to reach 1.56 billion by 2025.4 It is the leading cause of death and the second leading cause of lost disability-adjusted life-years worldwide.4 Randomized controlled clinical trials have show
Hypertension Management: Implications to Patients, Providers, and Payers
The Generic Pharmaceutical Association (GPhA) recently praised the Obama administration's fiscal 2011 budget proposal for the US Food and Drug Administration (FDA), which will increase the FDA's Office of Generic Drugs to $51.5 million, a $10-million increase compared with fiscal year 2010.1 In supporting the administration's attempt to strengthen access to generics, GPhA's President Kathleen Jaeger noted, "Generics also save our health care system money, a critical factor in these difficult economic times.
The most important scientific investigations in breast cancer are presented each year at the San Antonio Breast Cancer Symposium (SABCS). In its December 2009 meeting, several trends emerged, with strong implications to patient management and direct relevance to payers, patients, and providers.
Bisphosphonates: Not Just for Bone Loss Anymore
Several promising compounds for the treatment of rheumatoid diseases have been recently approved, are in phase 3 trials, or are about to undergo phase 3 evaluation. The following products are some of the main products that were featured at the 2009 annual meeting of the American College of Rheumatology (ACR).
Promising Therapies for Lupus, Gout, and More
Several new drugs developed for the treatment of a variety of cardiovascular diseases are currently in the pharmaceutical pipeline. The following findings were presented at the 2009 annual meeting of the American Heart Association (AHA).
Antiplatelet Agents in Pipeline Pitted against Clopidogrel
Results 1 - 7 of 7